首页> 外文期刊>Clinical medicine: journal of the Royal College of Physicians of London >A retrospective study of long-term outcomes in 152 patients with primary Sj?gren's syndrome: 25-Year experience
【24h】

A retrospective study of long-term outcomes in 152 patients with primary Sj?gren's syndrome: 25-Year experience

机译:152名原发性干燥综合征患者的长期预后回顾性研究:25年经验

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to evaluate the 25-year outcome of patients with primary Sj?gren's syndrome (pSS). One hundred and fifty-two patients diagnosed with pSS (American-European classification criteria) were retrospectively and descriptively analysed (1986-2011). Of all 152 patients, 55.9% were alive, 18.4% had died and 25.7% discontinued follow-up (mostly due to old age). Malignancy affected 28.3% and non-Hodgkin's lymphoma (NHL) affected 10.5%. The adjusted risk for development of NHL was an odds ratio (OR) of 10.5 (95% confidence interval [CI]: 3.05-36.42) in patients with vasculitis (p<0.001), and OR 3.4 (95% CI 1.05-11.2) in the presence of glandular complications (parotid swelling, lymphadenopathy) (p=0.041). Seventy-five patients (49.3%) developed other autoimmune diseases (autoimmune thyroid disease [15.8%], pulmonary fibrosis [7.2%] and vasculitis [10.5%]). Although the course of pSS is relatively benign, over 25 years patients experience more clinical complications than previously described. In addition, vasculitis and glandular manifestations were significant predictors for NHL.
机译:本研究的目的是评估原发性干燥综合征(pSS)患者的25年结局。回顾性和描述性分析了152例诊断为pSS(美国-欧洲分类标准)的患者(1986-2011年)。在所有152例患者中,有55.9%活着,有18.4%死亡,有25.7%停止随访(主要是由于老年)。恶性肿瘤影响28.3%,非霍奇金淋巴瘤(NHL)影响10.5%。血管炎患者的经调整的发生NHL的风险为优势比(OR)为10.5(95%置信区间[CI]:3.05-36.42)(OR <3.4)(OR 3.4)(95%CI 1.05-11.2)存在腺体并发症(腮腺肿胀,淋巴结肿大)(p = 0.041)。七十五名患者(49.3%)患有其他自身免疫性疾病(自身免疫性甲状腺疾病[15.8%],肺纤维化[7.2%]和血管炎[10.5%])。尽管pSS的病程相对较温和,但是25年来,患者的临床并发症比以前描述的更多。此外,血管炎和腺体表现是NHL的重要预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号